To NASDAQ OMX Copenhagen A/S Announcement No. 42-09 / Copenhagen, 13 October
2009
TopoTarget A/S
Symbion
Fruebjergvej 3
DK 2100 Copenhagen
Denmark
Tel: +45 39 17 83 92
Fax: +45 39 17 94 92
CVR-nr: 25695771
www.topotarget.com
Totect® manufacturing resumed
- Overall sales for the combined Q3-Q4 should not be adversely affected -
The manufacturing of Totect® has resumed and the supply of Totect® is on track
to meet customer needs. The supplier of TopoTarget's product Totect® in the US
had experienced difficulties which led to a temporary delay in the supply of
product from TopoTarget to its US distributors. The limited stock of product to
supply end-users will, as earlier announced, negatively affect reported sales
of Totect® for the Q3 period. The resumption of production should prevent any
adverse impact on overall Q3-Q4 periods.
“We are very happy that the manufacturing of Totect® has been resumed so that
the product again can become available to supply our distributors and we are
pleased that our manufacturer has been working diligently to resolve their
issues” Said John L. Parsons Jr. Chief Commercial Officer & President,
TopoTarget USA, Inc.
John L. Parsons Jr. further commented:“Totect® fulfills an important medical
need as the only approved treatment for cancer patients who experience an
extravasation or “leakage” of their anthracycline chemotherapeutic which causes
severe tissue damage and delays their cancer treatment.”
Totect® demonstrates 98% overall efficacy and should be proactively stocked
on-site and infused as soon as possible and within 6 hours of an anthracycline
extravasation. Totect® is indicated for the treatment of extravasation
resulting from IV anthracycline chemotherapy. Please visit www.totect.com for
full prescribing information.
TopoTarget retains its guidance for the 2009 year of a loss before tax of
approximately DKK 140 to DKK 160 million.
TopoTarget A/S
For further information, please contact:
Peter Buhl Jensen Telephone +45 39 17 94 99
CEO Mobile +45 21 60 89 22
